OMER Quote, Financials, Valuation and Earnings

GeoVax Labs, Inc. has a net margin of -- compared to Omeros Corp.'s net margin of -630.04%. Omeros Corp.'s return on equity of -- beat GeoVax Labs, Inc.'s return on equity of -433.69%.

Omeros Corp. has a consensus price target of $28.00, signalling upside risk potential of 163.65%. On the other hand GeoVax Labs, Inc. has an analysts' consensus of $9.63 which suggests that it could grow by 2302.05%. Given that GeoVax Labs, Inc. has higher upside potential than Omeros Corp., analysts believe GeoVax Labs, Inc. is more attractive than Omeros Corp..

Omeros Corp. has a beta of 2.485, which suggesting that the stock is 148.518% more volatile than S&P 500. In comparison GeoVax Labs, Inc. has a beta of 3.638, suggesting its more volatile than the S&P 500 by 263.848%.

Omeros Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. GeoVax Labs, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Omeros Corp. pays -- of its earnings as a dividend. GeoVax Labs, Inc. pays out -- of its earnings as a dividend.

Omeros Corp. quarterly revenues are --, which are smaller than GeoVax Labs, Inc. quarterly revenues of --. Omeros Corp.'s net income of -$21.2M is lower than GeoVax Labs, Inc.'s net income of -$6.3M. Notably, Omeros Corp.'s price-to-earnings ratio is -- while GeoVax Labs, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Omeros Corp. is -- versus 1.74x for GeoVax Labs, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Johnson & Johnson has a net margin of -- compared to Omeros Corp.'s net margin of 21.47%. Omeros Corp.'s return on equity of -- beat Johnson & Johnson's return on equity of 33.27%.

Omeros Corp. has a consensus price target of $28.00, signalling upside risk potential of 163.65%. On the other hand Johnson & Johnson has an analysts' consensus of $202.54 which suggests that it could fall by -1.36%. Given that Omeros Corp. has higher upside potential than Johnson & Johnson, analysts believe Omeros Corp. is more attractive than Johnson & Johnson.

Omeros Corp. has a beta of 2.485, which suggesting that the stock is 148.518% more volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.357, suggesting its less volatile than the S&P 500 by 64.296%.

Omeros Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 2.5% to investors and pays a quarterly dividend of $1.30 per share. Omeros Corp. pays -- of its earnings as a dividend. Johnson & Johnson pays out 84.8% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Omeros Corp. quarterly revenues are --, which are smaller than Johnson & Johnson quarterly revenues of $24B. Omeros Corp.'s net income of -$21.2M is lower than Johnson & Johnson's net income of $5.2B. Notably, Omeros Corp.'s price-to-earnings ratio is -- while Johnson & Johnson's PE ratio is 19.82x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Omeros Corp. is -- versus 5.40x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly & Co. has a net margin of -- compared to Omeros Corp.'s net margin of 31.72%. Omeros Corp.'s return on equity of -- beat Eli Lilly & Co.'s return on equity of 106.26%.

Omeros Corp. has a consensus price target of $28.00, signalling upside risk potential of 163.65%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,045.59 which suggests that it could grow by 1.16%. Given that Omeros Corp. has higher upside potential than Eli Lilly & Co., analysts believe Omeros Corp. is more attractive than Eli Lilly & Co..

Omeros Corp. has a beta of 2.485, which suggesting that the stock is 148.518% more volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.370, suggesting its less volatile than the S&P 500 by 62.965%.

Omeros Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.58% to investors and pays a quarterly dividend of $1.50 per share. Omeros Corp. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 44.39% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Omeros Corp. quarterly revenues are --, which are smaller than Eli Lilly & Co. quarterly revenues of $17.6B. Omeros Corp.'s net income of -$21.2M is lower than Eli Lilly & Co.'s net income of $5.6B. Notably, Omeros Corp.'s price-to-earnings ratio is -- while Eli Lilly & Co.'s PE ratio is 51.12x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Omeros Corp. is -- versus 15.86x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Vistagen Therapeutics, Inc. has a net margin of -- compared to Omeros Corp.'s net margin of -7525.97%. Omeros Corp.'s return on equity of -- beat Vistagen Therapeutics, Inc.'s return on equity of -76.57%.

Omeros Corp. has a consensus price target of $28.00, signalling upside risk potential of 163.65%. On the other hand Vistagen Therapeutics, Inc. has an analysts' consensus of $14.50 which suggests that it could grow by 288.74%. Given that Vistagen Therapeutics, Inc. has higher upside potential than Omeros Corp., analysts believe Vistagen Therapeutics, Inc. is more attractive than Omeros Corp..

Omeros Corp. has a beta of 2.485, which suggesting that the stock is 148.518% more volatile than S&P 500. In comparison Vistagen Therapeutics, Inc. has a beta of 0.561, suggesting its less volatile than the S&P 500 by 43.86%.

Omeros Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vistagen Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Omeros Corp. pays -- of its earnings as a dividend. Vistagen Therapeutics, Inc. pays out -- of its earnings as a dividend.

Omeros Corp. quarterly revenues are --, which are smaller than Vistagen Therapeutics, Inc. quarterly revenues of $258K. Omeros Corp.'s net income of -$21.2M is lower than Vistagen Therapeutics, Inc.'s net income of -$19.4M. Notably, Omeros Corp.'s price-to-earnings ratio is -- while Vistagen Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Omeros Corp. is -- versus 130.92x for Vistagen Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.